Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Volunteer In AstraZeneca's Covid Vaccine Test Dies In Brazil

Wed, 21st Oct 2020 20:40

(Alliance News) - A volunteer participating in clinical trials of the Covid-19 vaccine developed by Oxford University and AstraZeneca PLC has died in Brazil, officials said Wednesday, though it was unclear whether he received the vaccine or a placebo.

It is the first death reported in the various coronavirus vaccine trials taking place worldwide. 

However, organizers of the study said an independent review had concluded there were no safety concerns and that testing of the vaccine, developed with pharmaceutical firm AstraZeneca, would continue.

Media reports said the volunteer was a 28-year-old doctor working on the front lines of the pandemic who died of complications from Covid-19.

"All significant medical incidents, whether participants are in the control group or the Covid-19 vaccine group, are independently reviewed," Oxford said in a statement.

"Following careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue."

National health regulator Anvisa confirmed it had been "formally notified of the case on October 19" and had received a report on the independent review from the security and evaluation committee overseeing the study.

The D'Or Teaching and Research Institute, which is helping organize the tests in Brazil, said the independent review process had "raised no doubts about the safety of the study, and recommended it continue."

Oxford and AstraZeneca previously had to suspend testing of the vaccine in September when a volunteer in the UK developed an unexplained illness.

Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine.

Half the volunteers in the final-stage clinical trial – a double-blind, randomized, controlled study – receive a placebo, IDOR said.

Around 8,000 volunteers have been vaccinated so far in Brazil, and more than 20,000 worldwide, it said.

Study participants must be doctors, nurses or other health sector workers who come into regular contact with the virus.

Brazilian newspaper Globo said the deceased volunteer was a young doctor who had been treating Covid-19 patients since March in the emergency rooms and intensive care units at two hospitals in Rio de Janeiro.

He graduated from medical school last year, and was in good health prior to contracting the disease, family and friends told the newspaper.

Shares in AstraZeneca closed 1.8% lower at 7,920.00 pence on Wednesday in London.

source: AFP

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslode...

18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.